Lysozyme/Tracheal Antimicrobial Peptide‐Based Tissue‐Specific Expression Antimicrobial Plasmids Show Broad‐Spectrum Antibacterial Activities in the Treatment of Mastitis in Mice

The use of antibiotics is the preferred therapy for bacterial diseases. However, overusing antibiotics has led to the development of antibiotic resistance in bacteria, which is now a major public health concern. Therefore, in this study, the performance of lysozyme (LYZ)/tracheal antimicrobial peptide (TAP)-based tissue-specific expression antimicrobial plasmids (TSEAP) have been evaluated in the treatment of mastitis in mice. The results show that LYZ/ and TAP-based TSEAP could effectively reduce the clinical symptoms caused by Staphylococcus sciuri, Bacillus cereus, Escherichia coli, and Pseudomonas aeruginosa-induced mastitis. In addition, the studies of behavioral tests, parameters of weight growth, blood biochemistry, and organ coefficients comprehensively indicate that the transfection of LYZ/TAP-based TSEAP is safe in mice. Taken together, LYZ/TAP-based TSEAP have broad-spectrum antibacterial activity and may provide new insight for the non-antibiotic treatment of bacterial diseases.